MENA Market Research Company USA

Quick answer

BioNixus is a US-registered MENA market research company for US pharma and medtech teams that need primary fieldwork in Saudi Arabia, the UAE, Egypt and the wider GCC. Work is delivered from the BioNixus US office. Al Khobar, Dubai and Kuwait field teams run Saudi, UAE and Kuwait interviews. Custom studies run $10,000–$60,000. Scope is guaranteed in writing, not findings.

• US-registered, MEA-fielded

  Brief the Sheridan headquarters. Arabic–English fieldwork runs from Al Khobar, Dubai and Kuwait, with Cairo leadership for Egypt and North Africa.

• Physician and account-level cuts

  About 3,200 physicians across 48 countries, used when a syndicated US or GCC audit stops at the national average.

• Written scope, not a forecast promise

  Custom work is $10,000–$60,000. The tagline is “Guaranteed in writing.” That guarantee is sample, replacement and re-field — not accuracy of findings.

Who briefs a MENA market research company from the USA?

US brand, insights and market-access teams brief a healthcare market research partner when the decision sits in the Middle East or Africa and the dashboard they already buy does not cut far enough. The typical buyer is a US affiliate or a global insights lead in New Jersey, California, Illinois or Massachusetts who must take a Saudi, UAE or Egypt question to a US steering committee. This page is the money page for that outbound brief. It is not a domestic “market research company USA” directory — that comparison already lives on top healthcare market research companies in the USA and healthcare market research USA.

Two other buyers use the same page. First, foreign firms entering the United States — Gulf, European and Brazilian sponsors who need US market-entry research before they remit capital. Second, US consumer, automotive and B2B teams that need the same GCC fieldwork the pharma practice already runs. Start from the industries hub when the brief is not a physician or payer file.

BioNixus was founded in 2012 and is headquartered in Sheridan, Wyoming. Leadership offices are USA (Sheridan, WY), the United Kingdom (London) and Cairo (Sheikh Zayed). Field offices are Al Khobar, Dubai and Kuwait. The firm has served 118 clients in 48 countries and has run 127 studies in 2026 year-to-date (120 in 2025). Custom pricing is $10,000–$60,000. 40 client reviews sit on public profiles. Work is delivered from the BioNixus US office. Work is delivered from the USA offices and our field teams in Brazil and LATAM.

Why US teams commission Middle East healthcare market research

A US syndicated audit can size a national Rx or retail category. It rarely answers who will prescribe, tender or stock a product in Riyadh, Jeddah, Dubai, Abu Dhabi or Cairo. Middle East healthcare market research for US pharma is the commissioned work that names the physician, the hospital account, the payer and the Arabic instrument. Keep IQVIA or NielsenIQ for the US national cut. Brief BioNixus when the question moves to healthcare market research in Saudi Arabia, the UAE or Egypt.

Saudi Arabia market research for US companies is not a translated US discussion guide. SFDA, NUPCO and CHI are separate decisions. A US brand team that pastes a US ATU onto an Arabic sample will get polite answers and an unusable launch file. The same is true in the UAE, where MOHAP, DHA and DOH do not share one formulary. See how to choose a healthcare market research agency in Saudi Arabia and IQVIA alternative UAE primary research.

GCC physician survey work is the most common US-to-MEA healthcare brief: oncologists, endocrinologists, cardiologists, rare-disease specialists and hospital pharmacists, recruited in Arabic and English, with quotas by country and sector. BioNixus fields those samples from the Al Khobar, Dubai and Kuwait offices. The US project office in Sheridan writes the protocol, the quality plan and the steering-committee readout so the file can be defended in a US compliance review.

What a US-to-MEA study actually fields

A typical US-to-MEA programme is one decision, not a region-wide encyclopedia. The first page of the proposal names the decision, the countries, the respondents and the language. Healthcare briefs usually mix a quantitative GCC physician survey with qualitative payers or procurement interviews. Non-pharma briefs use the same field offices for buyers, distributors and consumers. HCP ATU studies and pharmacy mystery shopping are the two healthcare products US teams already recognise.

Saudi Arabia and the UAE are two samples. Do not brief “the GCC” as one cell unless the decision is truly regional and the instrument is designed that way. Egypt is a third sample when the US affiliate also owns North Africa. Qatar, Kuwait, Oman and Bahrain join when the brand already has a tender or a private-hospital list in those markets. Cross-links from this page go to Japan-to-MEA research, China-to-MEA research and Singapore-to-MEA research when the same US global team is coordinating several outbound corridors.

Chinese and Japanese sponsors already leave a public trail in the Gulf that a US competitor should not ignore. The Saudi Press Agency recorded more than 750 Chinese companies in the Kingdom and Chinese investment above SAR 31 billion (Saudi Press Agency, 25 September 2025). The Abu Dhabi Chamber, via WAM, put the UAE figures at more than 400,000 Chinese residents and over 17,000 Chinese companies (WAM, 11 June 2026). MFA China publishes the bilateral trade pages a US strategy team should date, not paraphrase (MFA China on Saudi Arabia). Those series describe stock and trade. They are not a demand curve for a US brand. Primary interviews still have to name the buyer.

US market entry research for foreign companies

The second job on this page is inbound. US market entry research for foreign companies is the commissioned file a Riyadh, Dubai, London or São Paulo committee needs before it funds a US subsidiary, a distributor, or an FDA-facing launch. The questions are not the same as a GCC physician survey. They include who the US buyer is, which state and channel, what tax and import file applies, and whether the first vehicle is a distributor, a state-registered seller, or a US entity. A dedicated industries insight for that brief is in draft as of 18 October 2026; until it is live, this money page is the indexed URL.

Gulf sponsors often arrive with a free-zone company and a US warehouse plan. That is not a demand file. European sponsors brief the USA and UK offices; Work is delivered from the USA and UK offices. Brazilian and other LATAM sponsors brief Sheridan with local field teams; Work is delivered from the USA offices and our field teams in Brazil and LATAM. The United States is fifty state tax regimes, a federal import stack, and commercial payers that do not behave like NUPCO or NICE. BioNixus scopes the research from Sheridan. It does not file the licence. Counsel and a registered agent do that. The research names the customer, the price and the channel the committee can interrogate.

Inbound US work still uses the same written guarantees as outbound MEA work. Scope, timing, replacement of non-qualifying respondents, a minimum sample, re-field at our cost, and a pilot fee credited to the main field. The tagline remains “Guaranteed in writing.” Findings are not guaranteed. Never read that sentence as guaranteed accuracy.

What a US-to-MEA brief must name, and how long field takes

A usable brief for a MENA market research company USA programme is one page. It names the decision, the countries, the respondents, the language, and the date the steering committee meets. “GCC physicians, wave one” is not a brief. “Oncologists in Riyadh, Jeddah and Dubai who have treated at least five patients on this class in the last twelve months, Arabic and English, readout before the 12 November US brand review” is a brief. The 48-hour proposal clock starts when those five items exist. Until they do, Sheridan will send a scoping note, not a price.

Typical US-to-MEA healthcare fieldwork, once the protocol is signed, runs four to eight weeks: instrument, back-translation, pilot, main field, and a written readout. Payer and hospital-procurement cells take longer than a GP or pharmacist sample. A GCC physician survey with country quotas is usually faster than a mixed qualitative–quantitative launch file. Non-pharma buyer interviews sit in the same window when the accounts are named. BioNixus will not invent a one-week national study to win a request-for-proposal. If a US team needs a number in ten days, the honest product is a small qualitative cell, not a 300-interview ATU.

The written quality gates are the same on every US-contracted file: replacement of non-qualifying respondents, a minimum sample, re-field at our cost if agreed quotas are missed, and a pilot fee credited to the main field. Those gates are why the slogan is “Guaranteed in writing.” They are not a claim that the findings are guaranteed, that a forecast will hit, or that a competitor share will match a later audit. US legal and compliance reviewers should read the protocol, not the homepage tagline, before they sign.

How the US office and the MEA field offices split the work

Sheridan writes the protocol, the sample plan, the quality gates and the readout. London joins when the same brand team sits in the UK. Cairo joins when Egypt or wider North Africa is in the sample. Al Khobar, Dubai and Kuwait recruit and moderate. Arabic instruments are written for the market, not machine-translated from a US English master and left untested. A Mandarin or Japanese cell is added only when the respondent is itself a Chinese or Japanese firm in the Gulf — not as a substitute for Arabic.

US teams already comparing domestic HCP survey companies should keep their US panel vendor for US physicians. An HCP survey company USA brief that stays inside the United States is a different page: healthcare market research USA and pharmaceutical market research USA. This money page is for the brief that leaves the US sample and enters MEA, or the brief that enters the US from abroad.

Japanese affiliates that sit in the US and also own a Gulf P&L should read Middle East market research for Japanese companies. APAC regional HQs that happen to book the work from a US cost centre should also see Middle East market research for Singapore companies. JETRO’s Middle East report shelf is useful context for those affiliates (JETRO Middle East reports); it is not a substitute for a named physician or buyer sample. Enterprise Singapore’s Abu Dhabi discovery programme is the matching public programme for Singapore tech firms (Enterprise Singapore).

Pricing, guarantees and what we will not claim

Custom studies typically run from $10,000 to $60,000. The price moves with countries, how hard the respondents are to reach, method and sample size. A written proposal follows within 48 hours of a usable brief. The written guarantees are: replace non-qualifying respondents free, a minimum sample, re-field at our cost if agreed quotas are missed, and a pilot fee credited to the main field. The slogan is “Guaranteed in writing.” That is a scope guarantee. It is not a claim of guaranteed accuracy, guaranteed findings, or a guaranteed forecast.

Work is delivered from the BioNixus US office. Al Khobar, Dubai and Kuwait field teams run Saudi, UAE and Kuwait interviews. Fieldwork in Japan, China or Singapore is scoped from Sheridan with local partners.

To brief a MENA market research company USA programme, use the contact form or email admin@bionixus.com. In the United States call +1-888-465-5557. In the United Kingdom call +44 7727 666682. In the Kingdom call the Al Khobar field office on +966 50 182 5336.

Related pages

• Middle East market research for Japanese companies
• Middle East market research for Chinese companies
• Middle East market research for Singapore companies
• Healthcare market research hub
• Industries hub
• Chinese companies entering Saudi Arabia and the UAE
• Australia–GCC market entry research